The Digital Price Tag Truce: Why Electronic Shelf Labels Survived New York’s Surveillance Ban

 

 The Digital Price Tag Truce: Why Electronic Shelf Labels Survived New York’s Surveillance Ban

**Subtitle:** *The One Fair Price Package is poised to become law, but the “kill switch” for digital tags was pulled at the last minute. Here is why your grocery store might still swap paper for pixels – and why the unions are furious.*

**Reading Time:** 8 Minutes | **Category:** Technology & Policy

## Introduction: The Click Heard Around the Aisle

It was the "click heard around the grocery store." For months, a coalition of state lawmakers, union leaders, and consumer advocates had been pushing for the most aggressive anti-surveillance law in the nation. The “One Fair Price Package” aimed to kill two birds with one stone: ban secret surveillance pricing, and ban the **electronic shelf labels (ESLs)** that make it possible .

The rallies were loud. The press releases were fierce. Attorney General Letitia James stood in the Bronx, accusing big tech of creating a "two-tiered system where the price depends on who you are, not what the product is" .

But when the final text of the bill emerged from the legislature’s grueling negotiations this month, a quiet but seismic shift had occurred.

The ban on electronic shelf labels is gone.

Instead, a last-minute carve-out has allowed digital price tags to survive . The bill now focuses narrowly on “surveillance pricing,” prohibiting the use of personalized data (like your credit score or zip code) to set live prices. But the technology itself—the digital screen sitting on the edge of the shelf—has been spared.

How did the digital label survive the political guillotine? The answer involves a powerful lobbying blitz by the grocery industry, a quiet pivot from technology manufacturers, and a bitter internal fight over the future of the checkout aisle.

In this deep-dive, we break down the "Phantom Menace" of dynamic pricing, explain why the lobbyists won the battle of the "waterbed effect," and tell you why your local shop may soon look more like a stock exchange floor than a grocery store.

> **The Bottom Line Up Front:** The war on surveillance pricing is winning. The war on digital price tags is losing. Lawmakers realized that banning the hardware (ESLs) doesn't stop the software (AI), and that digital tags are here to stay – they just need to be regulated, not eradicated.

## Part 1: The “Creepy” Technology – Why Everyone Wanted to Ban ESLs

To understand the politics of the bill, you have to understand the fear.

### The "Phantom Price" Problem

For decades, the supermarket was a bastion of price stability. You grabbed the bread, you looked at the little white sticker on the edge of the shelf, and you paid that amount at the register.

Electronic Shelf Labels change that physics .

An ESL is a small, paper-thin e-paper screen that replaces the adhesive price sticker. Connected to a central server via Wi-Fi or Bluetooth, it can update the price of a gallon of milk instantly—**in real time**.

At first, this was just a labor-saving device. It saved employees the trouble of walking around with a price gun. But coupled with AI, privacy advocates warned it becomes a surveillance tool.

“The nightmare scenario is that you walk down the chip aisle, and the shelf recognizes your face (via security cameras), pulls up your purchase history, and raises the price of the Doritos because it knows you’re addicted to salt,” said one tech privacy advocate.

### The "Surge Pricing" Aisle

The original, strict version of the bill (the Protecting Consumers and Jobs from Discriminatory Pricing Act, A.9396/S.8616) explicitly outlawed the use of these digital tags in grocery and drug stores . The reasoning was simple: **If you can change the price instantly, you will.**

Unions hated the tags because a centralized system could eliminate the job of the grocery clerk who manually updates prices—a task that is often a gateway to union membership .

Consumer groups hated them because they create a "two-tier" system where a person shopping at 9 AM pays $3.99, but the person shopping at 6 PM (when the algorithm detects higher traffic) pays $5.99.

"When the price can change with the push of a button, the consumer loses all bargaining power," argued Senator Michael Gianaris earlier this year .

## Part 2: The Great Carve-Out – How the Bill Changed

So, what happened? The most recent official amendment (A.9396B) tells the story .

The text of the bill still includes the definitions of ESLs and surveillance pricing, and it still makes **price discrimination based on personal data illegal**.

However, the outright ban on the *possession* of ESL technology was quietly removed. The final bill instead focuses on the *outcome*—banning the "surveillance pricing" activity .

### The "Waterbed Effect" Lobbying

There were two major forces behind this change.

**1. The Retail Efficiency Argument**

The grocery industry (represented by groups like the Food Industry Alliance) lobbied hard, arguing that ESLs are not tools of oppression, but tools of efficiency. In an era of high inflation, they argued that updating thousands of price tags manually costs millions of dollars—costs that are passed directly to the consumer .

"Banning the hardware is like banning the printing press because you hate the newspaper," one grocery executive argued. "We need digital tags to manage the complexity of modern supply chains."

**2. The "Future Tech" Promise**

The technology manufacturers, including giants like Vusion Group (formerly SES-imagotag), pivoted their PR strategy. Instead of talking about "dynamic pricing," they started talking about "price accuracy."

In a win for the manufacturers, the bill ultimately dropped the hardware ban. The feeling in Albany was that banning the *screen* was a losing battle. The *data* is the problem, not the pixel.

**The Human Touch:** For the 20-year veteran grocery clerk in Buffalo, this is a gut punch. For him, the physical act of stamping a can of beans with a price gun is a ritual of trust. It’s a promise that the price hasn't changed since he stamped it. The digital screen that can flip at corporate headquarters breaks that trust—and potentially eliminates his job.

## Part 3: The "Waterbed Effect" – Why Uniform Pricing Fails

There is another, more subtle reason the universal ban on pricing tech failed: economics.

### The Economics of 'One Price Fits All'

Supporters of a total ban argued that everyone should pay the same price for everything. While this sounds fair, economists point to the "waterbed effect" .

This is the idea that if you squeeze prices down in one place (forcing a low price for a senior citizen), prices bulge up somewhere else (a high price for a suburbanite) .

If the law forced every Kroger and Walmart to charge the exact same price to a billionaire on Park Avenue as to a single mother in the Bronx, the economists warned that the retailer would just stop offering discounts altogether.

"It is a blunt instrument," reads an analysis of similar price-fixing laws . "The bill would likely raise grocery prices, reduce competition, and harm the consumers it intends to help."

## Part 4: The Privacy Angle – The Data is the Poison, Not the Screen

The final bill’s survival mechanism is the "Privacy-By-Design" requirement. It doesn't ban the screen; it bans how the screen *connects to your phone*.

### The Bluetooth Beacon Ban

The biggest loophole closed in the bill was the connection between ESLs and smart phones.

The bill now strictly prohibits "price offers ... based on information gathered through ... passive or active scanning of a personal device" . This is crucial. It targets a specific practice where stores use ESLs as Bluetooth beacons to ping your phone.

Here’s how it works:

1.  You walk past the soda aisle.

2.  Your phone automatically connects to the store’s Wi-Fi/Bluetooth mesh.

3.  The algorithm knows you bought Coke two days ago.

4.  The digital price tag on the Pepsi flashes a lower price just for you to lure you away.

That creepy practice is explicitly banned. But the tag itself? It stays.

## Part 5: The Future of the Aisle – Static Screens, Dynamic Prices?

So, what does the grocery store of 2027 look like under the new rules?

### Scenario A: The "Costco" Model (Likely)

Most chains will likely keep the digital tags but treat them as **static price displays**. They will use the Wi-Fi tech to update prices across the whole store at midnight—the same way they update prices on the website.

You will still see a digital screen, but the price will be the same for everyone that day.

### Scenario B: The "Airline" Model (Unlikely – But Possible)

This is the "surveillance" scenario that the bill is trying to prevent. In this version, the price changes based on store traffic or local weather, but not on *your* personal data.

Because the bill bans personal data use, but does not ban *aggregate* data (e.g., "It's 5 PM and everyone is buying pasta, so we raise the pasta sauce price by 10 cents"), there is still a risk of "surge pricing" in the grocery aisle.

**The Human Touch:** The victory here is messy. The unions lost the battle on the hardware. The digital shelf is coming. However, the privacy advocates won the war on the data. The digital shelf will show you a price, but it won't (legally) be allowed to spy on your bank account to decide that price. In the world of 2026, that is called a "win."

## Frequently Asked Questions (FAQ)

**Q: Did New York ban electronic shelf labels (digital price tags)?**

**A:** No. The final version of the One Fair Price Package removed the outright ban on the technology. Grocery stores can still use digital screens to display prices .

**Q: What did the bill actually ban?**

**A:** It banned "surveillance pricing." This means stores cannot use your personal data (credit history, location, purchase history) to offer you a different price than the person standing next to you. It also bans stores from scanning your phone to offer a unique price .

**Q: Why did they stop trying to ban the hardware?**

**A:** The grocery industry lobbied heavily, arguing that digital tags are needed for operational efficiency (saving labor costs). Lawmakers decided it was better to regulate the *software* (the algorithm) rather than ban the *hardware* (the screen) .

**Q: Does this mean "surge pricing" is coming to groceries?**

**A:** Possibly, but with limits. Stores can use algorithms to adjust prices for *all* shoppers based on demand (e.g., raising the price of ice cream on a hot day). However, they cannot track *you* individually to charge you a special price .

**Q: Will this impact my loyalty card discounts?**

**A:** No. The bill explicitly allows discounts, including loyalty programs, coupons, and subscription pricing, as long as they are offered to all members on equal terms .

## Conclusion: The Screen Stays

We started this article with the fear of the "creepy" digital price tag—the device that knows too much and changes too fast. We end with a reality check.

The digital shelf label is not going away. It is too efficient. It saves too much labor.

However, the "creepy" part—the algorithm watching you—is being thrown in the trash. Under the new law, the digital tag is just a screen. It can change, but it cannot stalk.

**For the Consumer:**

Don't worry about the screen. Worry about the fine print. Make sure you understand how the store is using your loyalty card. The screen can't see you, but your card can.

**For the Retailer:**

You won the hardware battle. You can install the digital tags. But if you get caught using them to price based on a customer's race or tax bracket, the penalties are severe.

**The Bottom Line:**

The future of shopping is digital. The price will flicker. But the law finally caught up to the algorithm. New York didn't kill the pixel; it just cut the wire connecting the pixel to your wallet.

---

**#NewYorkLaw #SurveillancePricing #DigitalPriceTags #PrivacyRights #Albany #ConsumerProtection**

---

*Disclaimer: This article is for informational purposes only. It does not constitute legal advice. Bills are subject to final signature by the Governor.*

The “Snore Stopper”: Eli Lilly’s Zepbound Just Made Sleep Apnea a Metabolic Disease—And 39 Million Americans Could Benefit

 

 The “Snore Stopper”: Eli Lilly’s Zepbound Just Made Sleep Apnea a Metabolic Disease—And 39 Million Americans Could Benefit

**Subtitle:** *From 51 breathing stoppages per hour to just 26 — the FDA-approved obesity drug just added a game-changing indication. Here is why treating “fat tongue” might be the key to fixing America’s sleep crisis.*

**Reading Time:** 8 Minutes | **Category:** Health & Medicine

## Introduction: The Machine You Hate Wearing

Let’s be honest. If you have been diagnosed with obstructive sleep apnea (OSA), you know the drill. You go to a sleep lab. You get strapped to a mask. You try to sleep with a machine blowing air down your throat. And for millions of Americans, that machine — the CPAP — ends up in the closet within six months .

It is not your fault. The mask is claustrophobic. The hose gets tangled. The noise keeps your partner awake. The compliance rate for CPAP therapy is abysmal .

Now, Eli Lilly is offering an alternative: a weekly injection that actually treats the *cause* of the problem, not just the symptom.

On Thursday, June 4, 2026, Eli Lilly released new data reinforcing that Zepbound (tirzepatide) — the blockbuster weight-loss drug — is also a remarkably effective treatment for moderate-to-severe obstructive sleep apnea in adults with obesity .

The results are not just “good.” They are paradigm-shifting.

In two phase 3 clinical trials, patients taking Zepbound saw their Apnea-Hypopnea Index (AHI) — the number of times per hour their breathing stops — drop by an average of **25 to 29 events per hour**. Placebo patients saw just 5 to 6 fewer events . By the end of the year-long study, roughly **half of the patients on Zepbound had no sleep apnea symptoms at all** (remission) or only mild, non-symptomatic OSA .

This is the first pharmacologic treatment for sleep apnea in history. It works by targeting the root cause: obesity. Specifically, the fat stored around the upper airway — what researchers call "fat tongue" .

In this deep-dive, we will break down the clinical data that has the medical community buzzing, explain why losing 18-20% of your body weight changes your breathing, and analyze why this indication could open Zepbound up to **39 million American adults** — and what that means for Eli Lilly’s stock.

> **The Bottom Line Up Front:** Sleep apnea is not just a breathing disorder. It is a metabolic disease. Zepbound proves that by reducing neck circumference and tongue fat, you can effectively "cure" the condition. With the new FDA indication in hand, Eli Lilly is poised to disrupt a market currently dominated by machines — and the company’s stock and self-pay pricing strategy are central to that story .

## Part 1: The Numbers That Matter – How Zepbound Changes the AHI Score

Let’s start with the clinical data, because it is genuinely impressive.

### What is AHI?

The Apnea-Hypopnea Index (AHI) measures sleep apnea severity. It counts how many times per hour your breathing either stops (apnea) or becomes shallow (hypopnea) during sleep .

- **Moderate OSA:** 15–30 events per hour

- **Severe OSA:** 30+ events per hour

In the SURMOUNT-OSA clinical trials, the average patient started with **severe OSA**. In Study 5 (patients not using CPAP), the baseline AHI was 51.5 events per hour. In Study 6 (patients using CPAP), it was 49.5 events per hour .

### The Results

Here is what happened after 52 weeks of once-weekly Zepbound injections:

| Patient Group | Placebo AHI Reduction | Zepbound AHI Reduction | Difference |

| :--- | :--- | :--- | :--- |

| **Not using CPAP** | -5.3 events/hr | **-25.3 events/hr** | **-20.0** |

| **Using CPAP** | -5.5 events/hr | **-29.3 events/hr** | **-23.8** |

*Sources: *

In practical terms, a patient who woke up 50 times an hour (every 72 seconds) now wakes up 25 times an hour (every 2 minutes and 24 seconds). That is the difference between living in a state of constant exhaustion and actually getting restorative sleep.

### The Remission Data

Beyond the raw numbers, the most compelling stat is **remission**.

| Patient Group | Placebo Remission | Zepbound Remission | Difference |

| :--- | :--- | :--- | :--- |

| **Not using CPAP** | 15.9% | **42.2%** | +26.3% |

| **Using CPAP** | 14.3% | **50.2%** | +35.9% |

*Source: *

That’s right. In the CPAP-user group, **half of the patients** on Zepbound achieved an AHI of less than 5 (remission) or less than 15 with an Epworth Sleepiness Score of less than 10 (mild, non-symptomatic) .

### The Mechanism: It’s the Fat, Stupid

How does a diabetes/weight-loss drug fix sleep apnea?

The primary driver is **weight loss** — specifically, the loss of fat around the neck and upper airway . In the Zepbound trials:

- **Study 5 (non-CPAP):** Patients lost **16.1%** of their body weight (about 45 lbs)

- **Study 6 (CPAP):** Patients lost **17.3%** of their body weight (about 50 lbs)

Placebo patients lost just 2% .

When you lose significant weight, your neck circumference decreases. The soft tissue in your throat (the soft palate, the uvula, and yes, the tongue) gets smaller. The airway opens up. The snoring stops. The breathing stabilizes.

Moreover, Zepbound reduced **high-sensitivity C-reactive protein (hsCRP)** — a marker of systemic inflammation — and improved **systolic blood pressure** . These are critical secondary benefits, as sleep apnea is closely linked to hypertension and cardiovascular disease.

**The Human Touch:** For the 39 million Americans with sleep apnea, the current standard of care is a CPAP machine that 50% of patients stop using within a year . Zepbound offers an alternative that doesn’t involve a mask, a hose, or a machine. It is a needle once a week. For many, that trade-off is a no-brainer.

## Part 2: The Business of Breathing – Why Wall Street Is Excited

This is not just a medical breakthrough. It is a massive commercial opportunity.

### The Addressable Market

Obstructive sleep apnea affects roughly **39 million adults in the United States** . Of those, the vast majority are undiagnosed or untreated. The global market for sleep apnea devices is projected to exceed **$12 billion by 2030** .

Zepbound is now the **first and only FDA-approved pharmacologic treatment** for moderate-to-severe OSA in adults with obesity . That is a significant moat.

### The Self-Pay Strategy

One of the biggest barriers to GLP-1 drugs has been insurance coverage. Many employers have capped or excluded weight-loss drugs from their formularies.

Eli Lilly has addressed this head-on. In March 2026, the company announced that the Zepbound KwikPen is now available at **self-pay pricing starting at $299 per month for the 2.5mg starter dose** . The recommended maintenance doses (5mg, 10mg, 15mg) are higher, but the program significantly lowers the out-of-pocket burden for the uninsured or underinsured.

### The Oral Follow-Up

In September 2025, Lilly published detailed Phase 3 results for **orforglipron**, an oral (pill) version of a GLP-1 drug that is *not* an injectable . At the highest dose (36mg), patients lost an average of **27.3 lbs (12.4% body weight)** at 72 weeks. Nearly 60% lost at least 10% of their body weight.

If orforglipron is approved, it could eliminate the "needle fear" barrier entirely. It would also likely be cheaper to manufacture than the auto-injectors.

### The Acquisitions

Eli Lilly has been on a spending spree, investing **nearly $4 billion** to acquire three vaccine and infectious disease companies . While those acquisitions focus on shingles and surgical infections, they signal a broader ambition: Lilly does not want to be a "one-trick pony" relying solely on GLP-1s.

| Catalyst | Mechanism | Timeline | Impact |

| :--- | :--- | :--- | :--- |

| **Zepbound (OSA Indication)** | Injectable (tirzepatide) | Approved Dec 2024 | Addresses 39M patients |

| **Self-Pay Pricing** | $299/mo starting dose | Available March 2026 | Removes insurance barrier |

| **Orforglipron (Oral Pill)** | Daily GLP-1 | Phase 3 complete; Approval pending 2026-2027 | Expands market to needle-phobics |

| **Foundayo (Daily Pill)** | Oral GLP-1 | Approved April 1, 2026 | Daily pill for weight management |

*Sources: *

## Part 3: The Side Effects – What You Need to Know Before You Ask Your Doctor

No drug is a miracle. Zepbound has significant side effects that patients and doctors need to discuss.

### The Gastrointestinal Wall

The most common adverse events are gastrointestinal in nature :

- **Nausea** (up to 34%)

- **Diarrhea**

- **Vomiting**

- **Constipation**

- **Stomach pain**

- **Indigestion**

These are usually mild to moderate and tend to subside as the body adjusts to the medication. However, for some patients, they are intolerable.

### The Black Box Warning

Zepbound carries an FDA boxed warning regarding **thyroid C-cell tumors**. In rat studies, tirzepatide caused these tumors. It is not known whether it causes similar tumors in humans, but the drug should not be used in patients with a personal or family history of medullary thyroid cancer or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2) .

### The Cost

Even with the self-pay program, Zepbound is expensive. The $299 price applies only to the 2.5mg starter dose. The maintenance doses (5mg, 10mg, 15mg) are priced higher. For patients without insurance coverage, the annual cost could exceed $6,000.

### The Lifestyle Requirement

Zepbound is not a magic bullet. The FDA label specifies that the drug must be used in conjunction with a **reduced-calorie diet and increased physical activity** . Patients who do not modify their lifestyle will not achieve the 18-20% weight loss seen in the trials.

### The "Fat Tongue" Factor

It is also worth noting that the mechanism is indirect. Zepbound does not directly target the airway. It targets weight. For patients whose sleep apnea is *not* primarily caused by obesity (e.g., those with structural jaw issues or enlarged tonsils), the drug may be less effective.

**The Human Touch:** For the patient who has tried CPAP and failed, Zepbound offers a second chance. But it is not a free pass. You still have to diet. You still have to exercise. And you have to be willing to accept the nausea. The trade-offs are real. But for millions of people, those trade-offs are worth it.

## Part 4: The CPAP Disruption – A $12 Billion Industry in Peril

The sleep apnea market has long been dominated by device manufacturers: ResMed, Philips Respironics, Fisher & Paykel. Those companies sell CPAP machines, masks, hoses, and filters.

### The Recurring Revenue Model

CPAP is a "razor and blade" business. The machine is the razor. The masks, filters, and replacement parts are the blades. Once a patient is diagnosed with sleep apnea, the durable medical equipment (DME) company has a revenue stream for years.

Zepbound threatens that model.

If a drug can effectively put sleep apnea into remission, patients will stop buying masks. They will stop replacing filters. They will stop renting the machines.

### The ResMed Reality Check

ResMed stock fell 4% on the initial news of the Zepbound approval in December 2024 . Since then, the stock has recovered, as investors realize that the transition will be slow. Doctors are cautious. Insurance companies are slow to cover drugs. And CPAP remains the standard of care.

But the long-term trend is clear. As GLP-1 drugs become cheaper and more accessible, the device market will shrink.

### The Oral Threat

The orforglipron pill is even more threatening. If a patient can take a daily pill at home, rather than a weekly injection, the adherence rate will likely be higher. And if the pill is priced competitively (which oral small molecules generally are), it will be more accessible to a broader population.

| Therapy | Adherence Barrier | Annual Cost (est.) | Indicated For |

| :--- | :--- | :--- | :--- |

| **CPAP** | Mask discomfort, noise, travel | $500–$1,000 (supplies) | All OSA |

| **Zepbound** | Weekly injection, GI side effects | $3,600–$6,000+ | OSA with obesity |

| **Orforglipron (future)** | Daily pill | Unknown (likely lower) | OSA with obesity |

## Part 5: The Investment Case – Why Lilly Stock Is Still a Buy

Eli Lilly has already crossed the **$1 trillion market cap** threshold . The stock is up more than 45% over the past year . But many analysts believe there is still room to run.

### The EPS Explosion

In the first quarter of 2026, Lilly reported:

- **Revenue:** $19.8 billion (up 56% year-over-year)

- **EPS:** $8.55 (up 156% year-over-year)

*Source: *

The company is forecasting 2026 revenue between **$82 billion and $85 billion**, representing 28% growth at the midpoint, and EPS between **$35.50 and $37**, representing roughly 50% growth.

### The Valuation Premium

Lilly trades at roughly **29 times forward earnings** — a significant premium to the pharmaceutical industry average . That premium is justified by the growth trajectory, but it also means the stock is pricing in perfection.

### The Risks

There are significant risks:

- **Competition:** Novo Nordisk (Wegovy/Ozempic) and Pfizer are developing their own obesity/OSA drugs.

- **Pricing Pressure:** If Congress passes drug pricing reform, Lilly's margins could shrink.

- **Adverse Events:** Long-term safety data on tirzepatide is still limited. If rare side effects emerge, the stock will crater.

- **Execution:** The company is spending billions on acquisitions . Integrating those companies successfully is not guaranteed.

| Bull Case | Bear Case |

| :--- | :--- |

| GLP-1s become standard of care for obesity, diabetes, and sleep apnea | Pricing pressure from Medicare negotiations |

| Orforglipron captures needle-phobic market | Novo Nordisk launches superior drug |

| Acquisitions diversify revenue beyond GLP-1s | Long-term safety issues emerge |

| Self-pay model reaches uninsured patients | Margin compression from manufacturing scale |

**The Human Touch:** For the investor, Lilly is a story stock. It has the narrative (GLP-1s are transformative), the numbers (56% revenue growth), and the tailwinds (39 million potential OSA patients). But it is also expensive. The margin for error is thin. One bad trial readout, and the stock could drop 30%.

## Frequently Asked Questions (FAQ)

**Q: Is Zepbound approved for sleep apnea?**

A: Yes. The FDA approved Zepbound (tirzepatide) for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024 . It is the first and only pharmacologic treatment for OSA.

**Q: How does Zepbound help with sleep apnea?**

A: Zepbound causes significant weight loss (18-20% of body weight in clinical trials). This weight loss reduces fat deposits in the neck, tongue, and upper airway, which opens the breathing passage and reduces breathing disruptions during sleep .

**Q: Do I still need a CPAP machine if I take Zepbound?**

A: In the clinical trials, roughly half of patients on Zepbound achieved remission or mild non-symptomatic OSA after one year . For those patients, CPAP may no longer be necessary. However, treatment should be managed by a sleep specialist.

**Q: What are the side effects of Zepbound?**

A: The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and stomach pain. These are typically mild to moderate. Zepbound carries a boxed warning about thyroid C-cell tumors based on rat studies .

**Q: How much does Zepbound cost?**

A: Eli Lilly offers a self-pay program starting at $299 per month for the 2.5 mg starter dose . Maintenance doses are priced higher. Patients with insurance coverage may pay less, depending on their formulary.

**Q: Is Zepbound covered by insurance for sleep apnea?**

A: Coverage varies by plan. The new FDA indication may encourage more payers to cover Zepbound for OSA, but many employers have capped or excluded GLP-1 drugs from their formularies. Patients should check their specific plan.

**Q: Can I take Zepbound if I don't have obesity?**

A: The FDA approval for OSA is specifically for adults with obesity (BMI ≥30 kg/m²). For patients with OSA who are not obese, Zepbound is not indicated and may not be effective.

## Conclusion: The End of the Mask?

We started this article with a machine. The CPAP is bulky. It is uncomfortable. It is hard to travel with. And half of you have it sitting in a closet right now, gathering dust.

Zepbound is not a cure-all. It requires weekly injections. It causes nausea. It is expensive. And it works only if you lose weight.

But for the first time in history, there is an alternative to the mask. It is a pharmacologic treatment that addresses the underlying *metabolic* cause of sleep apnea, not just the *mechanical* symptom.

For the 39 million Americans who snore, gasp, and wake up exhausted, that is a revolution.

**For the Patient:**

Talk to your sleep specialist. If you have obesity and moderate-to-severe OSA, Zepbound may be an option. Be honest about your willingness to manage the GI side effects and commit to lifestyle changes.

**For the Caregiver:**

If your loved one refuses to wear the CPAP, this is a conversation starter. There is now an alternative. It is not easy, but neither is watching them struggle to breathe at night.

**For the Investor:**

Lilly is a story stock with real numbers. The sleep apnea indication opens up a massive new market. But the valuation is stretched. Watch the oral GLP-1 trials closely — those will determine whether Lilly becomes a long-term juggernaut or a short-term hype cycle.

**The Bottom Line:**

Eli Lilly just turned sleep apnea into a metabolic disease. The CPAP is no longer the only game in town. For patients, that means hope. For investors, that means opportunity. For the 39 million Americans who can't sleep, that means a future without the mask.

And that is worth losing sleep over.

---

**#EliLilly #Zepbound #SleepApnea #WeightLoss #GLP1 #Tirzepatide #LillyStock #HealthcareInnovation**

---

*Disclaimer: This article is for informational purposes only. It does not constitute medical advice. Always consult a physician before starting any new medication.*

The “People’s IPO”: Trump’s Radical Plan to Give Every American a Stake in OpenAI

 

 The “People’s IPO”: Trump’s Radical Plan to Give Every American a Stake in OpenAI

**Subtitle:** *From a $850 billion valuation to a $2 trillion sovereign fund — the president wants you to become a shareholder in the AI revolution. Here is how the “Public Wealth Fund” would work, why Sam Altman is cheering, and where Bernie Sanders draws the line.*

**Reading Time:** 9 Minutes | **Category:** Technology & Politics

## Introduction: The Air Force One Bombshell

The scene was classic Trump. Lounging aboard Air Force One, the president teased a policy so audacious, so unexpected, that it immediately dominated every news cycle.

"We're talking to the AI companies," Trump told reporters. "There's something very interesting about it, where it almost becomes a partnership with the American public. It's like you make them partners in this revolution. It would be a beautiful thing. ... It would make 'em rich" .

This was not a vague hypothetical. Behind the scenes, the Trump administration is in active discussions with OpenAI, Anthropic, and SpaceX about a precedent-shattering arrangement: the federal government would take an equity stake in these trillion-dollar AI giants, and the proceeds would flow back to you — the American citizen .

The timing is no accident. OpenAI is restructuring from a non-profit into a for-profit public benefit corporation, preparing for an IPO that could value the company at over $850 billion . Anthropic has filed confidentially for an IPO. SpaceX is set to launch the largest IPO in history on June 12.

Sam Altman, the CEO of OpenAI, has been lobbying the White House for this exact arrangement since early 2025 . His April policy document, "Industrial Policy for the Intelligence Age," called for a "Public Wealth Fund" that would allow "even those who have not invested in financial markets to have a stake in AI-driven economic growth" .

In this deep-dive, we will break down the two competing proposals on the table — the Altman-Trump "voluntary partnership" and Bernie Sanders' "50% stock tax" — explain the legal and logistical hurdles, and debate whether this is visionary policy or the most dangerous case of regulatory capture in American history.

> **The Bottom Line Up Front:** The proposal to give Americans a stake in AI companies is the most radical economic idea since the Alaska Permanent Fund. It turns AI from a threat into a dividend. But the details are still being written, and the fight over who gets what — and how much — is just beginning.

## Part 1: The Altman-Trump Blueprint – How the "Public Wealth Fund" Would Work

To understand the proposal, you have to look at a document OpenAI published in April 2026: a policy blueprint titled **"Industrial Policy for the Intelligence Age"** .

### The Core Mechanism

The plan is elegant in its simplicity.

1.  **Equity Donation:** AI companies (OpenAI, Anthropic, SpaceX) would voluntarily donate a small percentage of their equity — likely between **1% and 5%** — to the US government .

2.  **The Sovereign Fund:** The government would place these shares into a newly created **sovereign wealth fund** — an investment vehicle akin to what Norway uses to manage its oil wealth. Trump signed an executive order in February calling for the establishment of such a fund .

3.  **The Dividend:** The returns from this fund — the dividends and capital gains as the companies grow — would be distributed to American citizens. Some versions of the plan envision direct cash payments, similar to the Alaska Permanent Fund, which sends an annual check to every resident of the state .

"The concept is that even those who have not invested in financial markets can have a stake in AI-driven economic growth, regardless of their starting wealth or access to capital," OpenAI wrote in its proposal .

### Why Sam Altman Is Pushing This

At first glance, giving away equity to the government seems counterintuitive for a CEO. Why would Altman dilute his shareholders?

**The Political Shield:** AI is facing a growing populist backlash. People are scared of losing their jobs to automation. They are worried about the concentration of power. By giving the public a financial stake, Altman hopes to turn potential enemies into investors .

**The Regulatory Fast Lane:** Companies that voluntarily give equity to the government might find regulatory hurdles removed. It is a form of "patriotic insurance" against aggressive antitrust or safety crackdowns.

**The "Legitimacy" Play:** OpenAI is transitioning from a non-profit to a for-profit Public Benefit Corporation. Critics — including Elon Musk — argue this violates its founding mission. A government-sanctioned "public wealth fund" lends legitimacy to the new structure .

### The Trump Administration's Role

The administration has been in active discussions with OpenAI for over a year . The talks are being led by senior White House officials, and Treasury Secretary Scott Bessent has reportedly expressed interest in the concept .

"It's like you make them partners in this revolution," Trump said. "It would be a beautiful thing" .

| Stake Percentage | Source | Mechanism | Probability |

| :--- | :--- | :--- | :--- |

| **1% - 5%** | Industry discussions | Voluntary equity donation | Likely (if deal happens) |

| **50%** | Sen. Bernie Sanders (I-VT) | One-time stock tax | Unlikely (constitutional issues) |

| **10%** | Trump admin (Intel precedent) | Quid pro quo for subsidies | Possible hybrid model |

## Part 2: The Sanders Alternative – The 50% "Stock Tax"

Just as Trump was teasing his "partnership" plan, Senator Bernie Sanders dropped a legislative bomb.

### The AI Sovereign Wealth Fund Act

Sanders' proposal is far more aggressive. He wants to impose a **one-time, 50% tax on the stock of the largest AI companies** — OpenAI, Anthropic, and xAI (now part of SpaceX) — to be paid in shares rather than cash .

- **The Tax Rate:** 50% of the company's value.

- **The Payment Method:** Stock, not dollars.

- **The Governance:** The government would use its voting shares to secure board representation and block decisions "deemed harmful" .

Sanders argues that this is the only way to "guarantee that the trillions of dollars potentially generated by A.I. are used to improve the lives of all of us" .

### The Political Realignment

What is remarkable is that Sanders' idea has found resonance on the right. David Sacks, the investor who recently stepped down as Trump's AI and crypto czar, posted that he can see "why Sanders' idea resonates, including with many on the right" .

However, Sacks warned that it would "actually accelerate the corporate-government fusion we're already sliding toward" .

### The Unlikelihood of Passage

Sanders' bill is widely considered unlikely to pass a Republican-controlled Congress. The legal and constitutional questions are daunting. Can the government seize 50% of a private company's value without triggering a massive legal challenge? The Takings Clause of the Fifth Amendment suggests not.

But the very fact that Sanders is proposing it has shifted the boundaries of what Washington is willing to discuss. The Overton window has moved. What was once fringe is now mainstream.

**The Creative Angle:** The Sanders and Trump proposals represent two poles of AI governance. Sanders wants the government to take control because he distrusts the corporations. Trump wants the corporations to give a little because he wants them to keep innovating. The final policy will likely fall somewhere in the middle — but the debate itself is a sign of how fast the politics of AI are evolving.

## Part 3: The Critics – "Accelerating Corporate-Government Fusion"

Not everyone is celebrating. The proposal has drawn sharp criticism from across the political spectrum.

### The "Conflict of Interest" Problem

Nat Purser of the advocacy group Public Knowledge issued a stark warning. He cautioned against any setup that makes the government "less inclined to impose or enforce safety regulations because doing so might diminish the value of its own holdings" .

This is the core problem. The government is supposed to be the regulator. But if the government owns a stake in the companies it regulates, its incentive changes. A tough new safety rule might be good for the public — but bad for the stock price. Which way does the Treasury lean?

"The concern is not abstract," Purser noted. "Three days before Trump's profit-sharing comments, he signed an executive order asking AI companies to voluntarily submit frontier models for government testing up to 30 days before public release" . The word "voluntarily" is doing a lot of work.

### The Sacks Warning

David Sacks, who just left the administration, was even more direct. He warned that the plan would "accelerate the corporate-government fusion we're already sliding toward" .

In Sacks' view, the US is already moving toward a system where government and big tech are indistinguishable. An equity stake would be a giant step in that direction.

### The "Bailout" Fear

Former Microsoft employee Dare Obasanjo suggested on social media that "the groundwork is already being laid for a government bailout of OpenAI" .

The logic is compelling. If the government owns a stake, it has a vested interest in the company's survival. If OpenAI faces financial trouble, a bailout becomes more likely. The equity stake is a form of "too big to fail" insurance.

### The Legal Limbo

Even supporters of the idea admit that the legal mechanism is unclear. How does a private company transfer equity to the federal government? No one has written that law yet.

- **OpenAI:** Valued at over $850 billion, restructuring from non-profit to for-profit, preparing for an IPO. It closed a record funding round in March co-led by MGX, backed by Abu Dhabi's sovereign wealth fund .

- **Anthropic:** Has filed confidentially for an IPO .

- **xAI:** Merged into SpaceX, which is about to conduct the largest IPO in history .

Each has a different corporate structure, different investor base, and different fiduciary obligations. A one-size-fits-all equity transfer mechanism does not exist .

| Concern | Source | Likelihood |

| :--- | :--- | :--- |

| **Regulatory capture** | Nat Purser, Public Knowledge | High |

| **Corporate-government fusion** | David Sacks (former AI czar) | Moderate |

| **Government bailout risk** | Dare Obasanjo (former Microsoft) | Low (but rising) |

| **Legal/constitutional challenges** | Legal scholars | High |

| **Market distortion** | Free-market advocates | Moderate |

## Part 4: The Precedent – The Intel Model

One of the most convincing arguments for the plan is that the government has done it before.

### The 9.9% Solution

In 2025, as part of the CHIPS Act implementation, the US government took a **9.9% equity stake** in Intel Corporation . The rationale was national security: Intel is the only major American semiconductor manufacturer. Letting it fail or fall into foreign hands was not an option.

If the logic holds for chips — a foundational technology — why not for AI?

### The "Strategic Asset" Argument

The administration is categorizing AI alongside semiconductors, rare earth minerals, and quantum computing as a **"critical national security asset"** .

- **The Global Competition:** China is heavily subsidizing AI. The US argument is that to compete with state-owned enterprises, the US *must* have a government hand on the wheel.

- **The "Too Big to Fail" Logic:** If OpenAI collapses, the national security implications are severe. Taking an equity stake now is a hedge against a bailout later.

### The Difference

There is one crucial difference between the Intel stake and the AI proposal. The Intel stake came with specific industrial policy objectives tied to subsidies or procurement contracts. An AI equity program would be structurally different: it would aim to redistribute wealth from an entire category of companies to the general public, not to secure supply chains .

| Aspect | Intel Model | Proposed AI Model |

| :--- | :--- | :--- |

| **Rationale** | National security (supply chain) | Wealth distribution + legitimacy |

| **Mechanism** | Quid pro quo for subsidies | Voluntary donation or tax |

| **Stake Size** | 9.9% | 1-5% (voluntary) or 50% (tax) |

| **Beneficiary** | Government budget | Direct citizen dividends |

## Part 5: The Bigger Picture – The Alaska Model for the AI Age

The proposal that most closely resembles Trump's vision is the **Alaska Permanent Fund**.

### The Alaska Precedent

In 1976, Alaska voters established a sovereign wealth fund to manage the state's oil revenue. The fund owns a diversified portfolio of stocks, bonds, and real estate. Every year, it distributes a portion of its earnings to every resident of the state — the famous "Permanent Fund Dividend."

In 2025, that dividend was approximately **$1,600 per person** .

Trump's proposal would effectively create a national version of the Alaska fund, with AI companies as the "oil."

### The "AI New Deal"

OpenAI's Sam Altman has been promoting this concept for years. In 2021, he called for a "Moore's Law for Everything" — a universal basic income funded by taxes on AI-driven productivity gains. The "Public Wealth Fund" is the latest iteration of that vision .

### The Legitimacy Problem

The driving force behind the proposal is political necessity. Artificial intelligence remains broadly unpopular across the US population. Polls show that a majority of Americans are concerned about AI's impact on jobs, privacy, and democracy .

Industry leaders believe that transforming ordinary Americans into financial beneficiaries of AI's commercial success could fundamentally alter public perception of the technology .

"By doing that, they're gonna like it better," Trump said. "We're leading China. We're leading everybody in the world with AI, and we want to keep it that way" .

### What Comes Next

Trump said the meeting with AI companies will happen "next week" . No formal agenda has been announced. The planning remains at the discussion stage, with no companies confirmed and no legal framework in place.

The broader context is a country that has spent 18 months unable to agree on basic AI safety rules, let alone ownership structures. The EU has its AI Act. The US has a stalled executive order, a voluntary testing regime, and now two competing proposals to give the public a cut of the profits.

Whether any of it results in Americans actually receiving dividends from AI companies — or whether the conversation simply makes the companies look generous while changing nothing — will depend on details that nobody has written yet .

## Frequently Asked Questions (FAQ)

**Q: Is the government actually buying AI companies?**

A: No. The plan is for the government to **receive voluntary equity stakes** (shares) in the companies — likely as a donation, not a purchase. The companies would be giving away a small percentage of their value to the public .

**Q: Would I get a check?**

A: That is the goal. The returns from the government's shares would be funneled into a sovereign wealth fund, and the profits could be distributed as a direct dividend payment to all American households .

**Q: How much equity are we talking about?**

A: Industry discussions have centered on stakes ranging from **1% to 5%** . Bernie Sanders wants 50% . The Trump administration has not specified a number.

**Q: Is this legal?**

A: The administration is using the precedent of the Intel equity stake to argue its legality . However, a 50% "stock tax" would almost certainly face constitutional challenges.

**Q: Does this include Elon Musk's companies (SpaceX/xAI)?**

A: Yes. Trump has explicitly included SpaceX (which now owns xAI) in the discussions . However, given Musk's tense relationship with the administration, the negotiations would be complicated.

**Q: Is OpenAI on board?**

A: Yes. Sam Altman has been the most active advocate of the concept, raising it directly with Trump in early 2025 and returning to the idea in recent weeks .

**Q: When will we know if this is happening?**

A: Trump said he would meet with AI companies "next week" . However, the legal and logistical details could take months — or years — to resolve.

## Conclusion: The People's AI

We started this article with a number: $850 billion. That is OpenAI's valuation.

We end with a different number: **1% to 5%**. That is the stake that could be coming to you.

The "Public Wealth Fund" is the most radical economic idea since the Alaska Permanent Fund. It turns the AI revolution from a threat into a dividend. It transforms ordinary citizens from potential victims of automation into financial stakeholders in the technology that is reshaping the world.

Whether it happens depends on Sam Altman's willingness to share, Donald Trump's political calculus, and a legal system that has never considered a question quite like this.

But the fact that it is being discussed at the highest levels of government is a sign of how much the world has changed. AI is no longer just a technology. It is a political issue. And the question of who gets to own the future is now on the table.

**For the Citizen:**

The proposal is real. The discussions are happening. If you want a say in whether the government takes a stake in AI companies, let your representatives know. The decision is not just about money. It is about power.

**For the Investor:**

The uncertainty is real. If the government takes a 5% stake, your shares are diluted. If Sanders gets his 50%, the valuation math changes entirely. Watch the news from Washington closely.

**For the Skeptic:**

This is either visionary policy or the most dangerous case of regulatory capture in American history. The only way to know which is to follow the details — and to hold both the administration and the companies accountable.

**The Bottom Line:**

Donald Trump wants to make you a partner in the AI revolution. Sam Altman wants to give you a piece of his company. Bernie Sanders wants to take it for you.

The battle for the future of AI ownership has begun. And the stakes are higher than any of us can imagine.

---

**#Trump #OpenAI #AI #PublicWealthFund #SovereignWealthFund #SamAltman #BernieSanders #TechPolicy**

---

*Disclaimer: This article is for informational purposes only. Policy proposals are subject to change and legislative approval.*

Death of an Industry: Hollywood Workers Rise Up to Block the $110 Billion Paramount-WBD Merger

 

 Death of an Industry: Hollywood Workers Rise Up to Block the $110 Billion Paramount-WBD Merger

**Subtitle:** *From blue-collar grips to A-list directors, a city is fighting for its soul. As California prepares a historic lawsuit, workers warn that David Ellison’s empire comes at the cost of a “ghost town.”*

**Reading Time:** 9 Minutes | **Category:** Business & Entertainment

## Introduction: "The Biggest Thing We've Faced"

It was a scene more reminiscent of a labor strike from the 1930s than a corporate boardroom dispute in 2026. About 100 people gathered outside the Lumiere Music Hall in Los Angeles on Saturday, June 6—not to watch a film, but to protest the potential death of an industry .

Comedian Adam Conover, who lost his own show after the AT&T-Time Warner merger, stood at the podium and delivered a chilling prophecy .

"This industry is about to die, and that's why I feel so passionately about this issue," Conover told the crowd .

Conover and the assembled workers were rallying against the proposed $110 billion acquisition of Warner Bros. Discovery by Paramount Skydance, the upstart media company controlled by Oracle billionaire Larry Ellison and his son, David .

It was the first stop of a three-city "Main Street vs. The Merger" tour, organized by advocacy groups, the Writers Guild of America (WGA), and industry workers . The message was simple: this isn't just a corporate merger; it's an existential threat to the livelihoods of the "thousands and thousands of Grips and Gaffers. Drivers and Decorators. Builders and Boom operators" who make Hollywood run .

The rally came just days after a coalition of US states, led by California Attorney General Rob Bonta, began preparing a lawsuit to block the deal . For the workers on the line, the fight is personal. They have already lost 36% of their working hours since 2022. Sound stages that were nearly full in 2016 are now 62% empty . And they fear that a merger of two of the "Big Five" studios will be the knockout punch.

In this deep-dive, we will break down the four pillars of worker opposition: the job loss math, the "Ghost Town" prophecy from *Lost* creator Damon Lindelof, the precedent of the Penguin Random House case, and the unusual legal strategy that could actually block the deal.

> **The Bottom Line Up Front:** Hollywood is fighting for its life. The WGA and blue-collar unions have joined forces with A-list directors to argue that less competition means fewer productions—and fewer productions mean the end of the middle-class film industry. With 17,000 jobs already lost in California since 2019 and occupancy rates plummeting, the workers see this merger as the final nail in the coffin .

## Part 1: The Blue-Collar Hollywood

There is a persistent myth that Hollywood runs on trust funds and red carpets. Damon Lindelof, the creator of *Lost*, spent over 1,000 words on social media last month dismantling that myth .

"Hollywood, believe it or not, is a blue-collar town," Lindelof wrote. "It’s thousands and thousands of Grips and Gaffers. Drivers and Decorators. Builders and Boom operators. Camera teams and Caterers. And they’re all about to get f--ked" .

Lindelof was one of over 1,000 signatories to an open letter opposing the merger, a list that includes industry heavyweights like J.J. Abrams, Denis Villeneuve, Ben Stiller, and Kristen Stewart . Their unified message is that consolidation kills jobs—not just executive jobs, but the middle-class careers that sustain the Los Angeles economy.

### The Math of Destruction

The workers have the data to back up their fear.

- **36% Fewer Hours:** The International Alliance of Theatrical Stage Employees (IATSE), which represents 170,000 behind-the-scenes professionals, reported that its members worked roughly 36% fewer hours in 2025 than in 2022 .

- **17,000 Jobs Lost:** California has shed 17,234 entertainment positions from 2019 through 2023, according to the Milken Institute .

- **62% Occupancy:** The occupancy rate in Hollywood’s sound stages has fallen to 62% in the first half of 2025, down from nearly full occupancy in 2016 .

"The places we work with are closed," said Matt Radecki, a co-founder of the Different by Design post-production facility. "They’re gone, and they’re never coming back, and we don’t want to see that happen to HBO or CNN or CNN Films" .

### The "Ghost Town" Prophecy

Lindelof used a powerful metaphor to explain the logical outcome of the merger .

"When two storied backlots are owned by the same company, the outcome is intuitive — one becomes a Ghost Town," he wrote .

The fear is that Paramount will not keep both the Warner Bros. lot in Burbank and its own lot in Hollywood fully operational. The "synergies" that Wall Street demands—the $6 billion in cost savings that David Ellison has promised—will inevitably come from closing a facility . And when a backlot closes, the caterers, the drivers, the decorators, and the camera teams that service it lose their work.

**The Human Touch:** For the electrician who has wired the Warner Bros. backlot for 20 years, the merger is not a theoretical antitrust issue. It is a pink slip waiting to happen. The fight against the merger is a fight for the survival of a working-class Los Angeles that has already been battered by the decline of network television and the shift to streaming.

## Part 2: The Writers' Red Line

The Writers Guild of America (WGA) has been the most aggressive union in opposing the merger. Their opposition predates the Paramount deal; they condemned the possibility of a merger with Netflix last winter, and they have not softened their stance .

### A "Disaster" for Writers

In a joint statement issued immediately after Paramount outbid Netflix, the WGA East and West were unequivocal .

"The combination is different but the outcome is the same: the proposed Paramount-Warner merger would consolidate control of two major film and television studios and streaming services, and two of the largest employers of writers," the statement read .

"The loss of competition would be a disaster for writers, consumers and the entire entertainment industry. This merger must be blocked" .

Why are writers so scared? The answer is leverage. When there are five major studios (Disney, Universal, Warner, Paramount, Sony), writers have five potential buyers for their scripts. If Warner and Paramount become one, there are four. One less buyer means lower bids, less aggressive bidding wars, and less leverage for talent.

### The Conover Cautionary Tale

Adam Conover’s personal story illustrates the human cost of media consolidation. After AT&T’s 2018 acquisition of Time Warner, his TruTV show "Adam Ruins Everything" was canceled .

That cancellation didn't just affect Conover. It put employees, "countless" contractors, and more than 100 other people out of work .

"The places we work with are closed," Radecki echoed . "They’re gone, and they’re never coming back."

The writers fear that a merged Paramount-Warner will look at its combined slate of projects and decide that certain types of films—documentaries, mid-budget dramas, experimental comedies—are no longer worth the investment. They fear that the "30 films a year" promise is a mirage.

**The Human Touch:** For the screenwriter who spent five years developing a passion project, the number of buyers matters. If Warner and Paramount merge, there is one fewer door to knock on. That is not an abstract antitrust concept. It is the difference between a career and a hobby.

## Part 3: The Legal Precedent – The Penguin Random House Case

The workers and the WGA have a secret weapon in their fight: a legal precedent from 2022 that allows regulators to block mergers based on harm to **workers**, not just consumers.

### The 2022 Block

In 2022, the Justice Department successfully sued to block Penguin Random House’s bid to buy rival Simon & Schuster .

The argument was novel. Typically, antitrust law focuses on whether a merger will raise prices for consumers. In the Penguin Random House case, the government argued that the merger would hurt *authors*—the suppliers of labor—by reducing the advances they could command .

The court agreed. The merger was blocked.

### The "Labor Market" Argument

Ioana Marinescu, a University of Pennsylvania economist who wrote the Biden-era Justice Department’s guidelines on labor market issues, told Reuters that California could use the same argument .

"For some workers it could be that jobs at these two companies are really special, and this is really what they want," she said. "And there isn’t necessarily a very close substitute. And those are the people for whom it’s going to make an adverse impact" .

In other words, a grip who works on the Warner Bros. lot cannot simply walk across the street and get an equivalent job at Netflix or Apple. The skills are transferable, but the *employment ecosystem* is not. If Warner Bros. closes its lot, those specific jobs disappear.

### The Penguin Random House Playbook

Former Federal Trade Commissioner Alvaro Bedoya expressed optimism that California Attorney General Rob Bonta could replicate the Penguin Random House victory .

He argued that Bonta could successfully argue that the Paramount-Warner deal lessens competition among film studios, thereby indirectly affecting workers .

This is the "labor market" theory. It is the strongest legal tool the states have to block the merger. And it is the reason why workers, not just lawyers, are the face of the opposition.

**The Creative Angle:** The Penguin Random House case is the blueprint. If the states can prove that a merger of two studios will reduce competition for writers, directors, and crew, they can win. The precedent is recent. The case is strong. And the workers are the star witnesses.

## Part 4: The Corporate Defense – Does Ellison Have a Plan?

David Ellison is not a passive observer in this drama. He is spending billions to make this merger happen. He has a defense, and he is trying to sell it to the public.

### The "Netflix Threat" Argument

In a letter to California Attorney General Rob Bonta, Paramount chief legal officer Makan Delrahim argued that the merger is necessary for survival .

He pointed to Nielsen estimates showing that Paramount had only 5.8% of U.S. subscription VOD viewership, and Warner Bros. Discovery had 5.0%. By comparison, the top three streaming subscription platforms together capture 65% of all U.S. SVOD viewers — Netflix with 32.5%, Disney with 16.7%, and Amazon with 15.3% .

"Absent something transformative, neither party is positioned to grow to a scale where they would catch up to the leading streamers," Delrahim wrote .

The argument is simple: If Paramount and Warner do not merge, they will both be crushed by Netflix. The merger is not a grab for power. It is a fight for survival.

### The "30 Films a Year" Pledge

Ellison has repeatedly pledged that the combined studios will release at least 30 films per year—15 from Paramount, 15 from Warner .

He argues that this is more than Disney was releasing even before it acquired Fox. He is trying to prove that the merger will increase output, not decrease it.

However, critics note that churning out more films does not necessarily mean more money. Paramount itself has warned of "significantly lower theatrical revenue" in 2026 . The quality of the output matters more than the quantity.

### The $6 Billion Cost-Cutting Mandate

Here is the contradiction that workers are seizing on. While Ellison promises to increase output, he also promises to slash **$6 billion in operational costs** .

Workers are deeply skeptical that you can cut $6 billion without cutting jobs. The "30 films a year" pledge sounds good on a press release. But if you are cutting $6 billion, something has to give. And workers fear that what gives is their livelihood.

**The Human Touch:** For the post-production facility owner, Ellison’s $6 billion cost-cutting mandate is a direct threat. The studios will squeeze vendors to hit those savings. Independent facilities like Different by Design will be the first to feel the pain.

## Part 5: The State's Case – The Blue Wall of Attorneys General

The workers and the unions have an ally in the government.

### The Blue Wall

A coalition of at least 10 states is preparing a lawsuit to block the merger . The charge is being led by California and New York, with Connecticut, Colorado, Nevada, Oregon, Massachusetts, Tennessee, and Pennsylvania joining the probe [citation:?].

### The "Red Flags Everywhere" Assessment

California AG Rob Bonta has not been subtle about his views on the merger .

"The proposed deal has red flags everywhere," Bonta told reporters last month .

His office is examining the merger’s potential to result in higher prices, lower wages, fewer jobs, less choice, and less competition .

### The Consumer Lawsuit

Adding to the pressure, five Paramount subscribers filed a lawsuit in California federal court seeking to block the merger on antitrust grounds .

The lawsuit argues that the merger would give Paramount control of roughly 24% of the theatrical distribution market, strengthening its "ability and incentive to raise prices, reduce output, narrow slates, reduce quality and worsen consumer-facing terms" .

"If Paramount’s proposed acquisition of Warner Bros. Discovery is consummated, the combined firm would have increased ability and incentive to reduce theatrical film output and narrow release slates," the lawsuit reads .

The lawsuit claims a violation of Section 7 of the Clayton Antitrust Act, which bars mergers that substantially reduce competition .

### The Path Forward

Paramount has not yet responded to the potential state lawsuit. The company has repeatedly defended the deal, arguing that it "will create a stronger competitor" .

But the clock is ticking. The deal is set to close in September. If the states file their lawsuit and seek an injunction, the merger could be frozen for months—or killed entirely .

**The Human Touch:** For the attorney general in California, the merger is a test of the post-Trump antitrust enforcement landscape. For the worker in Hollywood, it is a matter of survival. The two are aligned. The blue wall is standing. And the workers are watching.

## Frequently Asked Questions (FAQ)

**Q: How many jobs has California lost in entertainment since 2019?**

A: California has shed 17,234 entertainment positions from 2019 through 2023, according to the Milken Institute .

**Q: What is the "Penguin Random House precedent"?**

A: In 2022, the Justice Department successfully blocked Penguin Random House’s acquisition of Simon & Schuster by arguing that the merger would harm authors (workers) by reducing competition for their labor. This precedent allows regulators to challenge mergers based on harm to the labor market, not just consumers .

**Q: Why are writers so opposed to the merger?**

A: The Writers Guild argues that consolidation reduces the number of buyers for scripts, which reduces competition, lowers wages, and limits opportunities for creative talent .

**Q: What is the "Ghost Town" prophecy?**

A: Damon Lindelof, creator of *Lost*, warned that if two storied backlots are owned by the same company, one will inevitably become a "ghost town" as the company consolidates operations to save costs .

**Q: Is the merger definitely happening?**

A: Not yet. A coalition of states, led by California and New York, is preparing a lawsuit to block the deal. The merger also faces scrutiny from the UK’s Competition and Markets Authority .

**Q: What is David Ellison promising?**

A: Ellison has pledged that the combined studios will release at least 30 films per year—15 from Paramount, 15 from Warner. However, he has also promised to slash $6 billion in operational costs, leading workers to doubt that jobs will be safe .

## Conclusion: The Town Versus the Tower

We started this article with a rally—100 people gathered in Los Angeles, fighting for their jobs. We end with a question: Can a city built on creativity survive consolidation?

The workers of Hollywood are not asking for a handout. They are asking for a chance to compete. They know that the industry has changed. They know that streaming has upended the old models. They know that Netflix is a juggernaut.

But they also know that two studios are better than one. They know that competition breeds opportunity. And they know that when the backlots go quiet, the caterers, the drivers, the decorators, and the camera teams lose their livelihoods.

**For the Worker:**

The fight is just beginning. The states are preparing a lawsuit. The unions are organizing. The voice of the industry is unified. Do not give up.

**For the Investor:**

The risk is real. The stock price gap between the deal value and the trading price reflects the market's assessment of regulatory risk. That gap could widen significantly if the states file their lawsuit.

**For the Movie Fan:**

A merger means fewer movies. It means less risk-taking. It means fewer mid-budget dramas and more Marvel sequels. If you love movies, you should oppose the merger.

**The Bottom Line:**

The $110 billion question is no longer "Will this deal close?" It is "Will Hollywood survive?" The workers have drawn a line in the sand. The attorneys general are preparing for war. And the fate of the industry hangs in the balance.

---

**#Paramount #WarnerBros #WritersStrike #Hollywood #Antitrust #MediaMerger #SaveHollywood**

---

*Disclaimer: This article is for informational purposes only. It does not constitute legal advice. Merger proceedings are fluid and subject to change.*